148 related articles for article (PubMed ID: 3550148)
1. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial.
Troner M; Birch R; Omura GA; Williams S
J Urol; 1987 Apr; 137(4):660-2. PubMed ID: 3550148
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.
Logothetis CJ; Samuels ML; Ogden S; Dexeus FH; Swanson D; Johnson DE; von Eschenbach A
J Urol; 1985 Sep; 134(3):460-4. PubMed ID: 2993671
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience.
Logothetis CJ; Dexeus FH; Chong C; Sella A; Ayala AG; Ro JY; Pilat S
J Urol; 1989 Jan; 141(1):33-7. PubMed ID: 2908950
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.
Maru A; Akaza H; Isaka S; Koiso K; Kotake T; Machida T; Matsumura Y; Nakagami Y; Niijima T; Obata K
Cancer Chemother Pharmacol; 1987; 20 Suppl():S44-8. PubMed ID: 3311445
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of chemotherapy in advanced urothelial carcinoma: with special reference to combination chemotherapy with adriamycin, cyclophosphamide and cisplatin (ACE chemotherapy)].
Tobisu K; Matsumoto K; Takai K; Kakizoe T
Nihon Hinyokika Gakkai Zasshi; 1987 Feb; 78(2):327-34. PubMed ID: 3613336
[No Abstract] [Full Text] [Related]
8. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.
Gagliano RG; Stephens RL; Costanzi JJ; Oishi N; Stuckey WJ; Grozea PN; Frank J; Crawford ED
Cancer Treat Rep; 1984; 68(7-8):1025-6. PubMed ID: 6430559
[No Abstract] [Full Text] [Related]
10. Chemotherapy and bladder cancer.
Garnick MB
J Urol; 1989 Jan; 141(1):107. PubMed ID: 2642307
[No Abstract] [Full Text] [Related]
11. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
[TBL] [Abstract][Full Text] [Related]
12. [Aggressive preoperative chemotherapy in infiltrating bladder carcinoma with a combination of cisplatin, cyclophosphamide and adriamycin. Preliminary report].
Martínez-Piñeiro JA; de la Peña JJ; Hidalgo L; Cisneros J; Jiménez de León J; Machuca J
Arch Esp Urol; 1986; 39(1):33-46. PubMed ID: 3707210
[No Abstract] [Full Text] [Related]
13. Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.
Torti FM; Harker WG
Cancer Chemother Pharmacol; 1983; 11 Suppl():S1-4. PubMed ID: 6357518
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant treatment of stages T2 to T4 bladder cancer with cis-platinum, cyclophosphamide and doxorubicin.
McCullough DL; Cooper RM; Yeaman LD; Loomer L; Woodruff RD; Boyce WH; Harrison LH; Assimos DG; Lynch DF
J Urol; 1989 Apr; 141(4):849-52. PubMed ID: 2926878
[TBL] [Abstract][Full Text] [Related]
15. Pre-cystectomy chemotherapy with sequentially administered cisplatin, cyclophosphamide and adriamycin in invasive transitional cell carcinoma of the bladder (preliminary report).
Guazzieri S; Sperandio P; Fandella A; Garbeglio A; Pegoraro V; Chiarion V; Fiorentino M; Pagano F
Prog Clin Biol Res; 1988; 260():599-602. PubMed ID: 3362909
[No Abstract] [Full Text] [Related]
16. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
Campbell M; Baker LH; Opipari M; Al-Sarraf M
Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy of invasive bladder cancer].
Kotake T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
[TBL] [Abstract][Full Text] [Related]
19. [Polychemotherapy treatment with cisplatin, adriamycin, 5-fluorouracil (FAP) and cisplatin, adriamycin and cyclophosphamide (CISCA) in advanced transitional carcinoma of the bladder].
Sánchez Romero JA; Ramírez Ruiz F; Romero Fernández L; Pastor Gaitán P; Murillo Capitán E
Actas Urol Esp; 1989; 13(4):240-2. PubMed ID: 2678934
[TBL] [Abstract][Full Text] [Related]
20. [[Neoadjuvant chemotherapy (cisplatin, doxorubicin, cyclophosphamide) in the treatment of invasive urothelial tumors of the bladder. Preliminary results of a prospective study concerning 22 patients].
Trifard F; Chrétien Y; Vallantin X; Collet C; Lachand AT; Dufour B
Ann Urol (Paris); 1988; 22(3):216-9. PubMed ID: 3401004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
